(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.15%.
Rani Therapeutics Holdings's earnings in 2026 is -$32,458,000.On average, 6 Wall Street analysts forecast RANI's earnings for 2026 to be -$25,256,373, with the lowest RANI earnings forecast at -$25,967,623, and the highest RANI earnings forecast at -$24,893,774. On average, 6 Wall Street analysts forecast RANI's earnings for 2027 to be -$27,390,125, with the lowest RANI earnings forecast at -$27,334,341, and the highest RANI earnings forecast at -$24,893,774.
In 2028, RANI is forecast to generate -$23,833,871 in earnings, with the lowest earnings forecast at -$27,334,341 and the highest earnings forecast at -$19,036,416.